Antivirals and Birth-Dose Vaccines Reduce Hepatitis B Transmission and Cancer Risk

Mitigating the Persistent Burden of Chronic Hepatitis B

Hepatitis B virus remains a leading global health priority, contributing to approximately 9.7 million annual cancer deaths, with liver cancer ranking as the third most common cause of oncologic mortality [1, 2]. While the overall cancer death rate has declined in some regions due to improved screening and tobacco control, the burden of infection-related malignancies remains disproportionately high in resource-limited settings [3, 4]. Vertical transmission from mother to child is the primary driver of chronic infection, yet global coverage for the critical birth-dose vaccine remains insufficient to achieve elimination goals [5, 6]. Although infant vaccination series starting at six weeks provide significant protection, they may not adequately address the risks associated with high maternal viral loads [7, 8]. A recent review provides a comprehensive update on the diagnostic protocols, vaccination strategies, and antiviral interventions necessary to manage this complex disease across the lifespan, offering clinicians a clear roadmap to reduce liver-related morbidity.

Transmission Dynamics and the Critical Window for Prevention

Hepatitis B is a DNA virus that spreads through percutaneous exposure, such as needle sticks, or mucosal exposure to infected blood, semen, or other body fluids. Despite the availability of effective prevention strategies, the global burden remains substantial. In 2022, there were approximately 1.2 million new hepatitis B virus infections worldwide, with 14,000 new cases occurring in the United States. These figures underscore the ongoing challenge of interrupting transmission chains, particularly in regions where the virus is endemic and healthcare resources are limited. The risk of mother-to-child transmission, the primary driver of the global chronic hepatitis B reservoir, is dictated largely by maternal serologic status. Infants born to mothers who are positive for both hepatitis B surface antigen (HBsAg, a viral envelope protein indicating active infection) and hepatitis B e antigen (HBeAg, a marker of high viral replication and infectivity) face a 70% to 90% risk of infection. In contrast, the transmission risk is significantly lower, ranging from 5% to 20%, for infants born to mothers who are HBsAg-positive but HBeAg-negative. These statistics highlight the necessity of identifying high-risk pregnancies through comprehensive prenatal screening to implement timely interventions. Clinical outcomes for neonates improve dramatically with immediate prophylaxis. The administration of the hepatitis B vaccine and hepatitis B immune globulin (a preparation of antibodies that provides immediate, short-term protection) within 12 to 24 hours of birth prevents approximately 94% of perinatal infections. For pregnant women with high serum hepatitis B DNA levels, the addition of maternal antiviral therapy further suppresses viral replication and reduces the transmission rate to less than 1%. However, a critical gap in public health implementation remains. Global coverage for the birth-dose hepatitis B vaccine was only 45% in 2024, leaving a majority of newborns without this essential protection and emphasizing the need for clinicians to advocate for immediate postnatal vaccination.

Age-Dependent Chronicity and Diagnostic Interpretation

Hepatitis B virus infection remains a significant global health challenge, affecting an estimated 254 million people worldwide. The clinical trajectory of the disease is heavily influenced by the age at which a patient first encounters the virus. The risk of developing a chronic infection, clinically defined as remaining hepatitis B surface antigen (HBsAg) positive for more than 6 months, is highest among the youngest patients. Specifically, the risk of chronicity is 90% if the infection occurs during infancy. This risk decreases as the immune system matures, falling to 30% in children aged 1 to 5 years. In contrast, the likelihood of progression to chronic disease is less than or equal to 5% in immunocompetent adolescents and adults, who are significantly more likely to clear the virus during the acute phase. Accurate clinical management relies on the precise interpretation of serologic testing and viral load quantification. The presence of HBsAg indicates an ongoing infection, serving as the primary marker for active carriage of the virus. Conversely, the presence of the antibody to HBsAg indicates immunity, whether acquired through vaccination or recovery from a prior infection. To further clarify a patient's history, clinicians evaluate the antibody to hepatitis B core antigen, which indicates either an ongoing or a past infection. Beyond these qualitative serologic markers, serum hepatitis B DNA levels are used to quantify virus-replication activity. This measurement of viral load is essential for assessing the phase of infection and determining the necessity of antiviral intervention to prevent long-term hepatic complications.

Staging Liver Disease and Identifying Treatment Candidates

Accurate staging of liver disease is essential for determining the clinical trajectory and therapeutic needs of patients with chronic hepatitis B. Clinicians utilize the assessment of liver inflammation and fibrosis to guide these decisions, primarily through the monitoring of alanine aminotransferase (ALT) levels and the application of noninvasive diagnostic tools. These tools include the Fibrosis-4 index (a scoring system that estimates hepatic scarring based on patient age, platelet count, and liver enzyme levels) and liver elastography (an ultrasound-based procedure that measures liver stiffness to evaluate the degree of fibrosis). Precise staging is critical because the 5-year cumulative risk of cirrhosis is 8% to 15% in cases of untreated chronic hepatitis B virus infection. Once a patient progresses to cirrhosis, the risk of malignancy increases substantially, with an annual hepatocellular carcinoma incidence of 3% to 5%. The initiation of antiviral therapy is strategically targeted to prevent these end-stage complications. Current clinical protocols dictate that antiviral treatment is recommended for all patients with chronic hepatitis B virus and cirrhosis, as these individuals face the highest immediate risk of liver failure and hepatocellular carcinoma. For patients who have not yet developed cirrhosis, the decision to treat is based on markers of active disease and potential progression. Specifically, antiviral treatment is recommended for those without cirrhosis who have high hepatitis B virus DNA levels accompanied by elevated ALT or evidence of significant inflammation or fibrosis. By identifying these high-risk candidates through routine serologic and noninvasive testing, physicians can implement suppressive therapy to reduce the long-term burden of liver-related morbidity.

Therapeutic Interventions and Long-Term Surveillance

The primary objective of managing chronic hepatitis B is the suppression of viral replication to prevent end-stage liver disease. Clinicians have two main classes of medications at their disposal: pegylated interferon alfa (an immunomodulatory agent administered via injection) and nucleos(t)ide analogues, specifically entecavir or tenofovir (oral medications that directly inhibit viral reverse transcription). These agents function by suppressing hepatitis B virus DNA replication, thereby halting the progression of hepatic damage. For patients adhering to these regimens, the clinical benefits are substantial. The findings demonstrate that antiviral therapies reduce the risk of hepatocellular carcinoma by approximately 50%, a critical reduction given the high baseline risk in patients with advanced fibrosis or cirrhosis. By maintaining low or undetectable viral loads, these therapies also decrease the likelihood of progression to liver failure. Effective management extends beyond pharmaceutical intervention to include rigorous longitudinal monitoring for malignancy. For patients identified as being at high risk for hepatocellular carcinoma, the study emphasizes a standardized monitoring protocol to ensure early detection. Specifically, patients at high risk of hepatocellular carcinoma should undergo surveillance with ultrasonography and alpha-fetoprotein testing every 6 months. This biannual frequency is designed to identify small, potentially resectable lesions before they progress to untreatable stages. Such systematic interventions are vital on a global scale, as hepatitis B virus infection causes approximately 1.1 million deaths annually. Through the combination of targeted antiviral therapy and consistent diagnostic surveillance, clinicians can significantly mitigate the mortality associated with this chronic viral burden.

References

1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer Journal for Clinicians. 2024. doi:10.3322/caac.21834

2. Parkin DM, Bray F, Ferlay J, Pisani P. Global Cancer Statistics, 2002. CA A Cancer Journal for Clinicians. 2005. doi:10.3322/canjclin.55.2.74

3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA A Cancer Journal for Clinicians. 2019. doi:10.3322/caac.21551

4. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet‐Tieulent J, Jemal A. Global cancer statistics, 2012. CA A Cancer Journal for Clinicians. 2015. doi:10.3322/caac.21262

5. Delamare H, Ishii-Rousseau JE, Rao A, et al. Proportion of pregnant women with HBV infection eligible for antiviral prophylaxis to prevent vertical transmission: A systematic review and meta-analysis. JHEP Reports. 2024. doi:10.1016/j.jhepr.2024.101064

6. Solomon-Rakiep T, Olivier J, Amponsah-Dacosta E. Towards contextualized complex systems approaches to scaling-up hepatitis B birth-dose vaccination in the African region: a qualitative systematic review. Frontiers in Public Health. 2024. doi:10.3389/fpubh.2024.1389633

7. Ansari A, Vincent J, Moorhouse LR, Shimakawa Y, Nayagam S. Risk of early horizontal transmission of hepatitis B virus in children of uninfected mothers in sub-Saharan Africa: a systematic review and meta-analysis.. Lancet Global Health. 2023. doi:10.1016/s2214-109x(23)00131-6

8. Brown RS, McMahon BJ, Lok AS, et al. Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and meta‐analysis. Hepatology. 2015. doi:10.1002/hep.28302